Chaperonin-containing tailless complex polypeptide 1 subunit 6A links with aggravating tumor features and disease-free survival in surgical gastric cancer patients: A long-term follow-up study - 20/08/22
, Changcai Guo a, Yong Chang a, Dapeng Wang aHighlights |
• | CCT6A was increased in gastric cancer tissues validated by both IHC and RT-qPCR. |
• | CCT6A correlated with advanced T stage and TNM stage in gastric cancer patients. |
• | CCT6A linked with poor DFS reflected by K-M curve and multivariate Cox's analyses. |
• | CCT6A showed a trend to relate to poor OS while lacked statistical significance. |
Abstract |
Background |
Chaperonin-containing tailless complex polypeptide 1 subunit 6A (CCT6A) promotes several gastrointestinal-cancer malignant behaviors, while its clinical value in surgical gastric cancer is not clear. Hence, we aimed to investigate this issue.
Methods |
Totally, tumor and adjacent specimens from 262 surgical gastric cancer patients were collected for measuring CCT6A protein level by immunohistochemistry (IHC) staining; meanwhile, specimens from 109 patients were used for evaluating CCT6A mRNA expression by reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Results |
CCT6A IHC score and CCT6A mRNA expression were upregulated in the tumor tissue compared with the adjacent tissue (both P<0.001). Besides, elevated CCT6A IHC score was correlated with larger tumor size (P<0.001), advanced T stage (P=0.001), N stage (P=0.003) and tumor node metastasis (TNM) stage (P=0.001). Meanwhile, increased CCT6A mRNA expression was associated with higher T stage (P=0.008) and TNM stage (P=0.020). Besides, CCT6A protein high (P=0.017) and CCT6A mRNA high (P=0.047) were correlated with unfavorable disease-free survival (DFS), whereas neither CCT6A protein nor CCT6A mRNA expression was related to the overall survival (OS) (both P>0.05). Additionally, the multivariable Cox's proportional hazards regression analysis revealed that CCT6A protein high was independently correlated with shorter DFS (adjusted hazard ratio (HR): 2.032, P=0.005), but not with OS.
Conclusion |
CCT6A is upregulated with its overexpression linking with advanced T stage, TNM stage and unfavorable DFS in surgical gastric cancer patients.
Le texte complet de cet article est disponible en PDF.Keywords : Chaperonin-containing tailless complex polypeptide 1 subunit 6A, Gastric cancer, Tumor node metastasis stage, Disease-free survival, }verall survival
Plan
Vol 46 - N° 7
Article 101913- août 2022 Retour au numéro
Article précédent
- Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients
- Ning Ma, Hui Qiao, Hanchuan Tao, Xinli Gan, Zhili Shan, Xiaomin Chen, Xiaojun Zhou
- Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease: A case report
- R.L. Goetgebuer, G.M.C. Masclee, A.A. van der Eijk, C.J. van der Woude, R.A. de Man, A.C. de Vries
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?